Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era (Advances in Therapy, (2022), 10.1007/s12325-021-01990-6)

Stefan Schreiber, Shomron Ben-Horin, Rieke Alten, René Westhovens, Laurent Peyrin-Biroulet, Silvio Danese, Toshifumi Hibi, Ken Takeuchi, Fernando Magro, Yoorim An, Dong Hyeon Kim, Sang Wook Yoon, Walter Reinisch*

*Corresponding author for this work

Research output: Contribution to journalComment/debate

Abstract

In the original article, a few errors were by the publisher during the typesetting process. The Graphical Abstract has been updated and a few minor formatting corrections have been made. The original article has been corrected.

Original languageEnglish
Pages (from-to)2281
Number of pages1
JournalAdvances in Therapy
Volume39
Issue number5
DOIs
StatePublished - May 2022

Fingerprint

Dive into the research topics of 'Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era (Advances in Therapy, (2022), 10.1007/s12325-021-01990-6)'. Together they form a unique fingerprint.

Cite this